Workflow
BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

Core Insights - BioRestorative Therapies, Inc. has appointed Crystal Romano to lead its global commercial operations and innovation, marking a significant step in the company's growth strategy [1][3] Company Overview - BioRestorative is focused on regenerative medicine, particularly stem cell-based therapies and products, with two main clinical development programs targeting disc/spine disease and metabolic disorders [4] - The company also operates a commercial BioCosmeceutical platform, developing products that utilize cell-based secretome containing exosomes, proteins, and growth factors [6][7] Leadership and Strategy - Crystal Romano brings over 19 years of experience in the medical and regenerative industries, recognized for her expertise in product development, commercialization, and navigating FDA regulations [2] - The CEO of BioRestorative emphasized the importance of Romano's role at a critical time for the company, aiming to expand its commercial footprint and unlock revenue opportunities [3] Clinical Development Programs - The Disc/Spine Program includes BRTX-100, a cell therapy candidate derived from a patient's own mesenchymal stem cells, currently in Phase 2 clinical trials for chronic lower back pain [4] - The Metabolic Program, ThermoStem, focuses on using brown adipose-derived stem cells to target obesity and metabolic disorders, with promising preclinical research indicating potential benefits for weight loss and metabolic health [5] Future Directions - BioRestorative aims to expand its BioCosmeceutical offerings through IND-enabling studies, seeking to pioneer FDA approvals in the emerging market [7]